Development of a Novel Breast Cancer Subtyping and Proliferation Gene Expression Diagnostic Test

Time: 9:30 am
day: Day Two Morning


• A RT-qPCR nucleic acid-based CE-IVD test for the detection and relative gene expression quantification of human mRNA target genes from pre-operative CNB or resected FFPE breast tumour tissue from patients with invasive breast cancer
• Breast cancer subtyping performance of the CE-IVD test is determined by concordance to that assigned by the current histopathology IHC reference methodology
• A novel ‘proliferative signature’ has been identified and included that allows for discrimination of Luminal A and Luminal B subtyping tumours over MKI67 alone